Irritable Bowel Syndrome Message Boards | The greatest insight comes from ....

the editorial. SIBO is a problematic diagnosis as explained in paragraph five. Only about 4% of the IBS population is anticipated to have SIBO. On the other hand 9-12% of the IBS-D suffers experienced a significant improvement of symptoms using the antibiotic. So of the 624 individuals that received the antibiotic from 56 to 87 individuals experience significant improvement while only 25 would be expected to have SIBO.

It seems the Pimental and colleague's focus may be moving away from SIBO to the colonic flora. The editor explained it this way "The most likely mode of action of rifaximin is a reduction in overall bacterial load, especially in the large bowel. This may lead to decreased bacterial fermentation and less bloating, possibly in combination with decreased secretion of bacterial products or host responses to bacterial products that contribute to the generation of symptoms."

While non-absorbable antibiotics have potential problems this finding may be bring us closer to an understanding of the causes of IBS. It will interesting to see how the FDA rules in March.

--------------------
STABLE: ♂, IBS-D 50+ years - Science of IBS

The FODMAP Approach to Managing IBS Symptoms
Evidence-based Dietary Management of Functional GI Symptoms: The FODMAP Approach
FODMAP Chart & Cheatsheet
The Role of Food & Dietary Intervention in IBS

Print Remind Me Notify Moderator